These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 37131252)

  • 1. H3K4me3-related lncRNAs signature and comprehensive analysis of H3K4me3 regulating tumor immunity in lung adenocarcinoma.
    Fan T; Zhu M; Muhammad S; Xiao C; Li S; Tian H; Liu Y; Xue L; Zheng B; Li C; He J
    Respir Res; 2023 May; 24(1):122. PubMed ID: 37131252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel m6A-Related LncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma.
    Shen Y; Wang S; Wu Y
    Cells; 2022 Aug; 11(15):. PubMed ID: 35954243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of RNA Methylation Modification-immune-related lncRNA Molecular Subtypes and Prognostic Scoring System in Lung Adenocarcinoma.
    Wang J; Shu J
    Curr Med Chem; 2024; 31(12):1539-1560. PubMed ID: 37680151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
    Shen M; Jiang K; Sui Y; Xu Z; Cui H; Wang Y; Zhang H; Xu Z; Xu W; Ding Q; Chen Y
    Lung Cancer; 2021 Oct; 160():84-91. PubMed ID: 34479175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma.
    Sun D; Zhang C
    Oncol Res; 2023; 31(5):753-767. PubMed ID: 37547766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
    Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.
    Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L
    Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Validation of 7-lncRNA Signature of Epigenetic Disorders by Comprehensive Epigenetic Analysis.
    Cao P; Li F; Xiao Y; Hu S; Kong K; Han P; Yue J; Deng Y; Zhao Z; Wu D; Zhang L; Zhao B
    Dis Markers; 2022; 2022():5118444. PubMed ID: 35237359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
    Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
    Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analysis of Tumor Immune Microenvironment and Prognosis of m6A-Related IncRNAs in Lung Adenocarcinoma.
    Shen Y; Hou N; Han F; Chen B; Shi J; Sun X
    Crit Rev Eukaryot Gene Expr; 2022; 32(5):77-91. PubMed ID: 35993946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma.
    Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J
    Front Genet; 2022; 13():838624. PubMed ID: 35928454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Expression of RTN1 in Lung Adenocarcinoma and 
Its Effect on Immune Microenvironment].
    Zhu S; Zu L; Xu S
    Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):385-395. PubMed ID: 35747917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD.
    Chen H; Shen W; Ni S; Sang M; Wu S; Mu Y; Liu K; Li N; Zhu L; Xu G
    Aging (Albany NY); 2021 Aug; 13(16):20684-20697. PubMed ID: 34438369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating bulk-RNA sequencing and single-cell sequencing analyses to characterize adenosine-enriched tumor microenvironment landscape and develop an adenosine-related prognostic signature predicting immunotherapy in lung adenocarcinoma.
    Han T; Wu J; Liu Y; Zhou J; Miao R; Guo J; Xu Z; Xing Y; Bai Y; Hu D
    Funct Integr Genomics; 2024 Jan; 24(1):19. PubMed ID: 38265702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
    Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
    J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-omics analysis of m
    Wu X; Bai Z
    Sci Rep; 2021 Oct; 11(1):20921. PubMed ID: 34686691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.
    Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S
    Front Genet; 2022; 13():862741. PubMed ID: 35368663
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of a pyroptosis-related lncRNA signature in the regulation of prognosis, metabolism signals and immune infiltration in lung adenocarcinoma.
    Zhou S; Cai Y; Xu Z; Peng B; Liang Q; Peng J; Yan Y
    Front Endocrinol (Lausanne); 2022; 13():964362. PubMed ID: 36034461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and validation of a ferroptosis-related LncRNA signature as a novel prognostic model for lung adenocarcinoma in tumor microenvironment.
    Wang Y; Lu G; Xue X; Xie M; Wang Z; Ma Z; Feng Y; Shao C; Duan H; Pan M; Ding P; Li X; Han J; Yan X
    Front Immunol; 2022; 13():903758. PubMed ID: 36016939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transmembrane Protein-Based Risk Model and H3K4me3 Modification Characteristics in Lung Adenocarcinoma.
    Fan T; Liu Y; Liu H; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Li C; He J
    Front Oncol; 2022; 12():828814. PubMed ID: 35392225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.